Humoral immune responses to recipient-derived leukemic blasts before and after immunization
. | Anti-human IgG avidin PE, MFI . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| Pt/dosage* . | Before study . | After 3 injections . | After 6 injections . | Control† . | |||
| 2/1 | 628 | 601 | 744 | 640 | |||
| 3/1 | 41 | 59 | 67 | 55 | |||
| 4/1 | 70 | 74 | 101 | 83 | |||
| 6/2 | 261 | 385 | 516 | 85 | |||
| 7/2 | 24 | 31 | 58 | 16 | |||
| 8/3 | 4 | 4 | 4 | NA | |||
| 9/3 | 292 | 341 | 309 | 270 | |||
. | Anti-human IgG avidin PE, MFI . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| Pt/dosage* . | Before study . | After 3 injections . | After 6 injections . | Control† . | |||
| 2/1 | 628 | 601 | 744 | 640 | |||
| 3/1 | 41 | 59 | 67 | 55 | |||
| 4/1 | 70 | 74 | 101 | 83 | |||
| 6/2 | 261 | 385 | 516 | 85 | |||
| 7/2 | 24 | 31 | 58 | 16 | |||
| 8/3 | 4 | 4 | 4 | NA | |||
| 9/3 | 292 | 341 | 309 | 270 | |||
Differences in MFI were not statistically significant between patients (P > .091). Patients 6 and 7 had a 2- to 3-fold increase of their postimmunization MFI compared with healthy controls. Patient 1 (dose level 1) experienced early disease progression. Patients 5 (dose level 2) and 10 (dose level 3) did not have enough blasts for immunologic studies.
PE indicates phycoerythrin; MFI, mean fluorescence intensity; and NA, not available.
The dose-escalation schedule began at 2 × 105 CD40L-secreting skin fibroblasts per injection (dose level 1), increasing in log increments to 2 × 107 (dose level 3). IL-2-secreting skin fibroblasts and recipient-derived blasts were administered at a fixed dosage throughout the study (2 × 107 per injection)
Controls consisted of pooled plasmas from healthy donors; not shown are the responses of the patients' plasmas against unrelated cells (no increase in the fluorescent signal)